Matt Coffey

5.0k total citations
98 papers, 3.6k citations indexed

About

Matt Coffey is a scholar working on Genetics, Infectious Diseases and Biotechnology. According to data from OpenAlex, Matt Coffey has authored 98 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Genetics, 57 papers in Infectious Diseases and 44 papers in Biotechnology. Recurrent topics in Matt Coffey's work include Virus-based gene therapy research (83 papers), Viral gastroenteritis research and epidemiology (57 papers) and Cancer Research and Treatments (44 papers). Matt Coffey is often cited by papers focused on Virus-based gene therapy research (83 papers), Viral gastroenteritis research and epidemiology (57 papers) and Cancer Research and Treatments (44 papers). Matt Coffey collaborates with scholars based in United States, United Kingdom and Canada. Matt Coffey's co-authors include Kevin J. Harrington, Alan Melcher, Richard G. Vile, Hardev Pandha, Johann S. de Bono, Katie Twigger, Peter J. Selby, Fiona Errington‐Mais, Brad Thompson and Timothy Kottke and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Matt Coffey

93 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matt Coffey United States	35	2.9k	2.0k	1.3k	1.1k	854	98	3.6k
Fiona Errington‐Mais United Kingdom	33	2.0k 0.7×	1.6k 0.8×	1.0k 0.8×	738 0.7×	518 0.6×	53	2.9k
Rosa María Díaz United States	39	2.5k 0.9×	2.0k 1.0×	1.6k 1.2×	514 0.5×	440 0.5×	97	3.7k
Anna Kanerva Finland	39	3.8k 1.3×	3.1k 1.6×	2.5k 2.0×	500 0.4×	995 1.2×	125	4.7k
Caroline J. Breitbach Canada	28	2.5k 0.9×	2.1k 1.1×	1.2k 1.0×	427 0.4×	538 0.6×	51	3.5k
Igor P. Dmitriev United States	35	3.2k 1.1×	1.9k 1.0×	2.7k 2.1×	637 0.6×	438 0.5×	83	4.1k
Nanhai G. Chen United States	34	2.2k 0.8×	1.5k 0.8×	1.3k 1.0×	296 0.3×	858 1.0×	97	3.5k
Steve H. Thorne United States	28	2.1k 0.7×	1.7k 0.9×	1.3k 1.0×	320 0.3×	569 0.7×	48	3.2k
Terry Hermiston United States	33	2.7k 1.0×	1.5k 0.7×	2.4k 1.9×	503 0.4×	489 0.6×	61	3.8k
Matthew Coffey United States	22	1.6k 0.6×	848 0.4×	842 0.7×	781 0.7×	479 0.6×	45	2.1k
Elizabeth J. Ilett United Kingdom	24	1.2k 0.4×	1.2k 0.6×	541 0.4×	397 0.4×	307 0.4×	38	1.9k

Countries citing papers authored by Matt Coffey

Since Specialization

Citations

This map shows the geographic impact of Matt Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Coffey more than expected).

Fields of papers citing papers by Matt Coffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Coffey. The network helps show where Matt Coffey may publish in the future.

Co-authorship network of co-authors of Matt Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Coffey. A scholar is included among the top collaborators of Matt Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Coffey. Matt Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Groeneveldt, Christianne, Diana J.M. van den Wollenberg, Rob C. Hoeben, et al.. (2024). Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies. Cancer Immunology Research. 12(3). 334–349. 3 indexed citations

Nawrocki, Steffan T., Kaijin Wu, Denice Tsao‐Wei, et al.. (2023). Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial. Clinical Cancer Research. 29(24). 5087–5103. 6 indexed citations

Mahalingam, Devalingam, Siqi Chen, Ping Xie, et al.. (2023). Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). British Journal of Cancer. 129(5). 782–790. 12 indexed citations

Arnold, Dirk, Eray Goekkurt, Alexander Stein, et al.. (2023). 1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study. Annals of Oncology. 34. S899–S899. 5 indexed citations

Migneco, G, Gina B. Scott, Jenny Down, et al.. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer. 9(3). e001803–e001803. 14 indexed citations

Evgin, Laura, Amanda L. Huff, Timothy Kottke, et al.. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research. 7(5). 828–840. 13 indexed citations

Mahalingam, Devalingam, Grey Wilkinson, Kevin H. Eng, et al.. (2019). Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clinical Cancer Research. 26(1). 71–81. 142 indexed citations

Igase, Masaya, Shusaku Shibutani, Matt Coffey, et al.. (2019). Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma. Molecular Therapy — Oncolytics. 15. 49–59. 14 indexed citations

Roulstone, Victoria, Malin Pedersen, Joan Kyula, et al.. (2015). BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Molecular Therapy. 23(5). 931–942. 38 indexed citations

10.

Roulstone, Victoria, Khurum Khan, Hardev Pandha, et al.. (2014). Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical Cancer Research. 21(6). 1305–1312. 42 indexed citations

11.

Chakrabarty, Romit, Hue Tran, Yves Fortin, et al.. (2014). Evaluation of homogeneity and genetic stability of REOLYSIN® (pelareorep) by complete genome sequencing of reovirus after large scale production. Applied Microbiology and Biotechnology. 98(4). 1763–1770. 7 indexed citations

12.

Carew, Jennifer S., Claudia M. Espitia, Weiguo Zhao, et al.. (2013). Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death and Disease. 4(7). e728–e728. 56 indexed citations

13.

Karapanagiotou, Eleni, Victoria Roulstone, Katie Twigger, et al.. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. 18(7). 2080–2089. 151 indexed citations

14.

Twigger, Katie, Victoria Roulstone, Joan Kyula, et al.. (2012). Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer. 12(1). 368–368. 46 indexed citations

15.

Harrington, Kevin J., Eleni Karapanagiotou, Victoria Roulstone, et al.. (2010). Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clinical Cancer Research. 16(11). 3067–3077. 94 indexed citations

16.

Kottke, Timothy, Geoff Hall, José S. Pulido, et al.. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. Journal of Clinical Investigation. 120(5). 1551–1560. 68 indexed citations

17.

Twigger, Katie, Laura Vidal, Christine L. White, et al.. (2008). Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical Cancer Research. 14(3). 912–923. 88 indexed citations

18.

Errington‐Mais, Fiona, Lynette P. Steele, Robin Prestwich, et al.. (2008). Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity. The Journal of Immunology. 180(9). 6018–6026. 150 indexed citations

19.

Lane, Maureen E., Jeanne M. Fahey, Nancy Hamel, et al.. (2007). In vivo synergy between oncolytic reovirus and gemcitibane in ras-mutated human HCT116 xenografts. Cancer Research. 67. 4812–4812. 4 indexed citations

20.

Vidal, Laura, Alan Melcher, Kate Newbold, et al.. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies.. Molecular Cancer Therapeutics. 6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact